Section Arrow
MIRM.NASDAQ
- Mirum Pharmaceuticals
Quotes are at least 15-min delayed:2026/10/21 00:43 EDT
Regular Hours
Last
 85.07
+2.83 (+3.44%)
Day High 
85.55 
Prev. Close
82.24 
1-M High
94.57 
Volume 
633.30K 
Bid
77.03
Ask
88
Day Low
82.315 
Open
82.75 
1-M Low
77.78 
Market Cap 
5.34B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 81.77 
20-SMA 84.33 
50-SMA 92.68 
52-W High 130 
52-W Low 63.232 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-14.08/0.48
Enterprise Value
5.66B
Balance Sheet
Book Value Per Share
-0.16
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
186.37M
Operating Revenue Per Share
2.23
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
EYPTEyePoint Inc.0.4052-0.0348-7.91%-- 
RXRXRecursion Pharmaceuticals3.66+0.05+1.39%-- 
MRNAModerna242.08+15.19+6.69%-- 
IBRXImmunityBio8.77+0.35+4.16%-- 
SLNSilence Therapeutics Plc19.61+0.03+0.15%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.